Biocon Limited · NSE:BIOCON
Biocon — Investor Presentation (December 2009)
43 slides from Biocon's investor presentation, December 2009
Slide 1: Corporate Presentation
August 2009 Corporate Presentation December 2009 August 2009 1
Slide 2: Disclaimer
Disclaimer Disclaimer Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 3: From Enzymes to Bio-Pharma
From Enzymes to Bio-Pharma TRANSFORMATIONAL $363 m GROWTH PHASE Branded Formulations & New Drugs EVOLUTIONARY Generics GROWTH PHASE $100 m & Services INCREMENTAL $25 m GROWTH PHASE Enzymes EXIT IPO ENZYMES 1978 1998 2004 2007 2009 3
Slide 4: Risk-Balanced Business Model
Risk-Balanced Business Model MARKETING THRUST RESEARCH FOCUS MANUFACTURING BASE 4
Slide 5: Corporate Structure
Corporate Structure ~ 8% 60% ~ 32% 100% 100% Biocon SA Biocon Research Overseas Subsidiary R&D 50% 78% (Dubai) (Germany) 5
Slide 6: Integrated Drug Development Capabilities
Integrated Drug Development Capabilities ACROSS THE VALUE CHAIN 6
Slide 7: Business Ethos
Business Ethos POSITIONING: Leading producer of generics & bio-similars and a frontline biopharmaceutical innovator. STRATEGY: Investing in new drug development and penetrating global markets for bio-similars through partnerships. RISK MITIGATION: Selection of New Drugs based on validated targ
Slide 8: Corporate Mission: Affordable Innovation
Corporate Mission AFFORDABLE INNOVATION Develop and offer the world’s most affordable Diabetes Therapies Innovate and deliver the most affordable biologics for cancer and auto-immune diseases Forge strategic partnerships that create global market access Commercialize novel biologics with a “Made
Slide 9: Research & Development
Research & Development 9
Slide 10: Key Focus Areas of R&D
Key Focus Areas of R&D Diabetes, Oncology & Auto-immune Diseases ANTI EGFR MAb ANTI CD6 MAb (T1h) BVX20 MAb (Anti-CD20) IN105 (Oral Insulin) CONJUGATED ANTIBODIES GENERIC BIOLOGICS rh-INSULIN INSULIN ANALOGS TRASTUZUMAB BEVACIZUMAB 10
Slide 11: Innovation Matrix
Innovation Matrix Foundation for Leadership in Innovation Eg. Immuno-conjugates IATRICa EXISTS CREATIVITY Building Market Leadership in Innovation Eg. Microbial r-DNA bio-similars: rh-Insulin, GCSF INCREMENTAL INNOVATION UNKNOWN KNOWN Creating Market Leadership in Innovation Eg. Oral Insulin BREAKTH
Slide 12: R&D Pipeline Progress
R&D Pipeline Progress Business model: Leverage our strong financial position to develop novel drugs for licensing and co-promoting with multiple marketing partners in various global markets Research programs in advanced stages Oral Insulin or IN-105 and T1h or Anti-CD6 Monoclonal antibody 12
Slide 13: IN-105 – Oral Insulin
IN-105 – ORAL INSULIN • Phase III: Completed initial dose range finding studies. Currently in the middle of a long-term efficacy and safety study (CTRI/2008/091/000276) in Indian patients with Type II diabetes. • Presented a paper on IN105 at the session on Novel Therapies during the European Associ
Slide 14: Phase 2a findings - Absorption is proportional to dose
Phase 2a findings - Absorption is proportional to dose 14
Slide 15: T1h – Anti-CD6 Monoclonal Antibody
T1h – Anti-CD6 Monoclonal Antibody • Psoriasis Phase II – Treatment phase is complete. Final report to be submitted to regulators by Nov 2009. • Double-blind Placebo-controlled Phase III study (TREATPLAQ) in Psoriasis to be initiated in Q1CY2010. • RA Phase II report to be submitted to the regulator
Slide 16: T1h: Response Pictures 0.4mg/kg
T1h: Response Pictures 0.4mg/kg once every 4 weeks Day 1 Day 29 16
Slide 17: T1h: Response Pictures 0.8 mg/kg
T1h: Response Pictures 0.8 mg/kg once every 4 weeks Day 1 Day 8 Day 29 17 Day 57
Slide 18: Strategic Alliances
BS Biocon STRATEGIC ALLIANCES 18
Slide 19: Biocon - IATRICa
Biocon - IATRICa Invested in IATRICa in 2008, a US-based start-up Biotech firm To co-develop novel, anti-cancer molecules based on a proprietary immuno-conjugation technology licensed from Johns Hopkins University, USA. Bio-hybrid molecules for targeted immunotherapy are considered to be the n
Slide 20: EGFR Antibody-CpG DNA (Active antibody)
EGFR Antibody-CpG DNA (Active antibody) – More effective and durable inhibition of colon cancer 20
Slide 21: Biocon - Mylan
Biocon - Mylan An exclusive collaboration for the development, manufacturing and commercialization of complex biogenerics / biosimilars, especially MAbs. Biocon is well positioned in both novel biologics and bio- generics owing to its early investments in R&D and manufacturing. Mylan brings in
Slide 22: Biocon - Amylin
Biocon - Amylin An exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic. Partnership is specific to Diabetes segment. Amylin brings in its knowledge on peptide therapeutics. Biocon brings in its recombinant DNA technology, large-scale manufacturin
Slide 23: Products & Markets
Products & Markets 23
Slide 24: Global presence: ~75 countries
Global presence: ~ 75 countries Europe, USA, Latin America, South East Asia and the Middle East. 24
Slide 25: Therapeutic Segments
Therapeutic Segments INSUGEN® STATIX® Myokinase® 25
Slide 26: Research Services
Research Services 26
Slide 27: Expertise
Expertise Synthetic Chemistry Medicinal Chemistry Process R & D Chemistry Services Analytical Custom Polymer Chemistry R&D Manufacturing Biology & Biologics Biologics/ Custom Early Biology Preclinical Manufacturing Services Pharmace- Formulation Regulatory Consulting & utical Support Development Ser
Slide 28: Business Model
Business Model FTE Service Project- Integrated Business Based Service Drug Business Models Models (Milestone Discovery Payment ) Collaborative Partnership 28
Slide 29: Growth Trajectory: 2000 - 2009
Growth Trajectory: 2000 - 2009 2000 2009 Area 20,000 Sq Ft Facility 1,000,000 Sq Ft Facility Chemical Hoods ~60 800+ Biology Includes Biochemical and Cell-based assay Simple Biology laboratory Capabilities (automated liquid handling systems) ADME-T, hERG channel assays Focused Libraries, Design
Slide 30: Broad Customer Base
Broad Customer Base CAGR ~ 25% Revenues (USD Mn) 50 45 40 On going collaborations with ~ 60 35 companies worldwide currently 30 25 20 Collaboration with seven of top ten 15 “BIG” Pharmaceutical Companies 10 5 0 2002-03 2003-04 2004-05 2005-06 2006-07 2007-08 2008-09 H1 FY2010 Broad & Extensive Custo
Slide 31: Talent Pool
Talent Pool SCIENTIFIC TALENT POOL Strong team of 1200+ Scientists 31
Slide 32: Milestones
Milestones 2000 Establishment 2002 CAP accreditation for Central Laboratory 2003 NABL accreditation for Central Laboratory Started Clinical Trial Operations with Phase III trial for Biocon 2004 Established Human Pharmacology Unit & Bioanalytical Research Lab 2005 Started offering Clinical Resear
Slide 33: Comprehensive Services
Comprehensive Services Clinical Trial Management Central Clinical Laboratory Development Human Pharmacology Unit Regulatory Services Bioanalytical Clinical Data Management Research Laboratory & Biostatistics 33
Slide 34: Expertise
Expertise Therapeutic Patient Products Areas Population Oncology Small Molecules Neonatal Diabetology Biologics Pediatric Metabolic disorders Vaccines Adult Rheumatology Devices Dermatology Spread of Cardiovascular our clinical project sites in India Gastroenterology Ne
Slide 35: Clinical Research Experience
Clinical Clinical Research Research Experience Experience Phase-wise Therapeutic Area-wise (Phase I-IV) Break-up of Patients by Therapeutic areas More than 5000 patients have participated 35
Slide 36: Talent Pool
Talent Pool Clinigene is a rapidly growing organization with over 150 highly skilled and experienced professionals 36
Slide 37: The Clinigene Advantage
The Clinigene Advantage Quality Credentials Have conducted some large studies involving up to 1500 subjects Vast experience in Oncology, Diabetes & Osteoporosis segments Secured 100% approval from regulators with Clinical Trial Applications Flexibility offered – Services customized to each
Slide 38: Financial Performance
FINANCIAL PERFORMANCE 38
Slide 39: Revenues FY09 vs. FY08
Revenues FY 09 vs. FY 08 $m $ 363 Rs. Cr $ 273 55% 76% $ 199 $ 208 28% $ 102 13% 16% $ 49 4% $ 44 4% 3% $ 14 $ 12 $ 9 39
Slide 40: P&L FY09 vs. FY08
P & L FY 09 vs. FY 08 Particulars FY 09 % on FY08 % on Rs. Cr / $ m Rev Rs. Cr / $ Rev m Revenues 1,673 / 363 1,090 / 273 EBIDTA 387 / 84 23% 342 / 86 31% PBT 260 / 57 16% 231 / 58 21% Tax 12 / 3 13 / 3 PAT # 240 / 52 14% 225 / 56 21% Exceptional Item (147) / 32 240 / 60 # after Minority interest be
Slide 41: Revenues H1 FY10 vs. H1 FY09
Revenues H1 FY 10 vs. H1 FY 09 $m $ 229 Rs. Cr $ 160 49% $ 112 64% 36% $ 83 12% 19% 13% $ 29 $ 30 3% $6 41
Slide 42: P&L H1 FY10 vs. H1 FY09
P & L H1 FY 10 vs. H1 FY 09 Particulars H1 FY10 % on H1 FY09 % on Rev Rev Rs. Cr / $ Rs. Cr / $ m m Revenues 1,098/ 228 734 / 159 EBIDTA 236 / 49 21 168 / 36 22 PBT 158 / 32 14 106 / 23 14 Tax 23 / 4 2 8 /2 1 PAT 132 / 27 12 100 / 21 13 Exceptional - (60) / (13) Item H1 FY 10 $ 48 Rs. H1 FY 09 $ 46
Slide 43: Thank You
Thank You Thank You 43